Clinical trial
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System…
NCT00210314 · International Extranodal Lymphoma Study Group (IELSG), Other · Completed
Key facts
| NCT number | NCT00210314 |
|---|---|
| Title | Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma |
| Official title | Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B Cell |
| Intervention type | Drug, Radiation |
| Interventions | high dose methotrexate, high dose cytarabine, radiotherapy |
| Enrollment | 79 |
| Start date | Jul 1, 2003 |
| Primary completion | Sep 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 30, 2015 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: